Drug intelligence / Profile preview

H7N9c

Development stage: Phase 1
Lead developer: Novartis
Modality: Vaccines & Immunotherapeutics

Overview

H7N9c is a cell culture-derived, inactivated monovalent subunit influenza virus vaccine developed by Novartis Vaccines. It is designed to evaluate the safety and immunogenicity of different doses, both with and without adjuvant, in adults aged 18 to less than 65 years. The vaccine aims to stimulate the immune system to produce antibodies against the A/H7N9 influenza virus, thereby providing protection against infection.

Beyond the preview

Go deeper on H7N9c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H7N9c.

Explore the full profile